ProQR completes patient enrollment in phase 2/3 sepofarsen trial

ProQR Therapeutics completed patient enrollment in the phase 2/3 Illuminate trial, investigating sepofarsen for the treatment of Leber congenital amaurosis 10, according to a press release.
The randomized trial includes 36 patients 8 years of age or older. Patients will receive sepofarsen at the target registration dose, a low dose of sepofarsen or sham treatment. The primary endpoint is the mean change in best corrected visual acuity from baseline to month 12 in those receiving the registration dose vs. sham, according to the release.
“In surpassing our enrollment target, we (Read more...)

Full Story →